Morphine, buprenorphine, and other similar drugs are known as opioid drugs. Opium is dark brown, resinous material obtained from poppy capsule called opium containing alkaloids. Opioids include morphine, buprenorphine, noscapine, thebaine, etrophine, and other similar substances. Morphine is principle alkaloid in opium and is described prototype of this class of drugs. Opioids have sedative and analgesic effects, and are commonly used for pain management. Opioids are commonly indicated in traumatic, visceral, ischaemic, postoperative burn, and cancer pain. The growth in the market can be primarily attributed to the growing prevalence of cancer worldwide.
Market Dynamics
The key drivers contributing to the global morphine, buprenorphine and other drug market's growth is the increase in prevalence of diseases such as cancer, chronic pain (post-surgical pain, lower back pain), arthritis, and fibromyalgia. Several narcotic drugs are recommended for the management of moderate to severe pain in cancer patients. For instance, according to Centers for Disease Control and Prevention (CDC) cancer is one of leading causes of deaths in the U.S. Furthermore, according to U.S. Cancer Statistics of 2021 in 2018 1,708,923 Americans were diagnosed with cancer. Thus, owing to prevalence of cancer and use of opioids for treatment of cancer is expected to drive the market growth.
Key features of the study
- This report provides an in-depth analysis of the morphine, buprenorphine, and other drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the morphine, buprenorphine and other drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Purdue Pharma, Sun Pharmaceuticals, Pfizer Inc. , West Ward Pharmaceuticals, Teva Pharmaceuticals, Piramal Pharmaceuticals, Hikama Pharmaceuticals, Indivior PLC, Oreoxo AB, Camurus AB, and Novartis
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The morphine, buprenorphine, and other drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global morphine, buprenorphine, and other drugs market
Market Segmentation
- By Drug (Revenue, USD Bn, 2021-2033)
- Morphine
- Buprenorphine
- Noscapin
- Thebaine
- Etrophine
- By Application (Revenue, USD Bn, 2021-2033)
- Pain Management
- Opioid Addiction Treatment
- Others
- By Route Of Administration (Revenue, USD Bn, 2021-2033)
- Injectable
- Oral
- Transdermal
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Purdue Pharma
- Sun Pharmaceuticals
- Pfizer Inc.
- West Ward Pharmaceuticals
- Teva Pharmaceuticals
- Piramal Pharmaceuticals
- Hikama Pharmaceuticals
- Indivior PLC
- Oreoxo AB
- Camurus AB
- Novartis
